The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 21 01 2020
accepted: 28 02 2020
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 26 6 2020
Statut: epublish

Résumé

To assess the association of low- vs. guideline-recommended high-intensity cystoscopic surveillance with outcomes among patients with high-risk non-muscle invasive bladder cancer (NMIBC). A retrospective cohort study of Veterans Affairs patients diagnosed with high-risk NMIBC between 2005 and 2011 with follow-up through 2014. Patients were categorized by number of surveillance cystoscopies over two years following diagnosis: low- (1-5) vs. high-intensity (6 or more) surveillance. Propensity score adjusted regression models were used to assess the association of low-intensity cystoscopic surveillance with frequency of transurethral resections, and risk of progression to invasive disease and bladder cancer death. Among 1,542 patients, 520 (33.7%) underwent low-intensity cystoscopic surveillance. Patients undergoing low-intensity surveillance had fewer transurethral resections (37 vs. 99 per 100 person-years; p<0.001). Risk of death from bladder cancer did not differ significantly by low (cumulative incidence [CIn] 8.4% [95% CI 6.5-10.9) at 5 years) vs. high-intensity surveillance (CIn 9.1% [95% CI 7.4-11.2) at 5 years, p = 0.61). Low vs. high-intensity surveillance was not associated with increased risk of bladder cancer death among patients with Ta (CIn 5.7% vs. 8.2% at 5 years p = 0.24) or T1 disease at diagnosis (CIn 10.2% vs. 9.1% at 5 years, p = 0.58). Among patients with Ta disease, low-intensity surveillance was associated with decreased risk of progression to invasive disease (T1 or T2) or bladder cancer death (CIn 19.3% vs. 31.3% at 5 years, p = 0.002). Patients with high-risk NMIBC undergoing low- vs. high-intensity cystoscopic surveillance underwent fewer transurethral resections, but did not experience an increased risk of progression or bladder cancer death. These findings provide a strong rationale for a clinical trial to determine whether low-intensity surveillance is comparable to high-intensity surveillance for cancer control in high-risk NMIBC.

Identifiants

pubmed: 32203532
doi: 10.1371/journal.pone.0230417
pii: PONE-D-20-01946
pmc: PMC7089561
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0230417

Subventions

Organisme : HSRD VA
ID : I01 HX002780
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Urol Oncol. 2018 May;36(5):257-264
pubmed: 29395957
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
BMC Urol. 2017 Sep 6;17(1):78
pubmed: 28877694
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Cancer. 2019 Sep 15;125(18):3147-3154
pubmed: 31120559
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
J Natl Cancer Inst. 2003 Apr 16;95(8):588-97
pubmed: 12697851
Cancer. 2006 Apr 1;106(7):1527-35
pubmed: 16518814
J Natl Cancer Inst. 2009 Apr 15;101(8):571-80
pubmed: 19351919
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086
Health Serv Res. 2016 Oct;51(5):2002-19
pubmed: 26839976
JAMA Netw Open. 2018 Sep;1(5):
pubmed: 30465041
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
Cancer. 2011 Dec 1;117(23):5392-401
pubmed: 21780079
Can J Urol. 2016 Apr;23(2):8198-203
pubmed: 27085823
JAMA Surg. 2018 Sep 1;153(9):850-851
pubmed: 29617542
Urology. 2017 Dec;110:84-91
pubmed: 28916254

Auteurs

Michael E Rezaee (ME)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
Section of Urology Dartmouth Hitchcock Medical Center, Lebanon, NH, United States of America.

Kristine E Lynch (KE)

VA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, United States of America.

Zhongze Li (Z)

Biomedical Data Science Department, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.

Todd A MacKenzie (TA)

Biomedical Data Science Department, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.

John D Seigne (JD)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States of America.

Douglas J Robertson (DJ)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.

Brenda Sirovich (B)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.

Philip P Goodney (PP)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.

Florian R Schroeck (FR)

White River Junction VA Medical Center, White River Junction, VT, United States of America.
Section of Urology Dartmouth Hitchcock Medical Center, Lebanon, NH, United States of America.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States of America.
Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH